Author of

• 32067

  +

  EP1.11 - Screening and Early Detection (ID 201)

  • Event: WCLC 2019
  • Type: E-Poster Viewing in the Exhibit Hall
  • Track: Screening and Early Detection
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall

  • 32092

    +

    EP1.11-20 - A Panel of Liquid Biomarkers for Early Response Capturing of NSCLC Therapies in Advanced Stages (Now Available) (ID 632)

    08:00 - 18:00  |  Author(s): Sabina Janciauskiene
    • Abstract
    • Slides

    Background
    

    CT scans are the gold standard to measure treatment success of Non-Small Cell Lung Cancer (NSCLC) therapies. In recent years, liquid biopsies became an adequate diagnostic tool especially in advanced disease stages.

    Method
    

    Here, we investigated very early tumor response of patients receiving chemotherapy or targeted therapies using a panel of already established and explorative liquid biomarkers. Blood samples from patients were taken at baseline and day + 1 for the chemotherapy cohort (n = 25) and at baseline, day +7 and +14 for the targeted therapy cohort (n = 25). DNA mutational load, a panel of 17 microRNAs, glycodelin, glutathione disulfide, glutathione, soluble caspase-cleaved keratin 18 (M30 antigen) and soluble keratin 18 (M65 antigen) were measured using serum and plasma from patients. Baseline and first follow-up CT scan were evaluated by an experienced radiologist and correlated with biomarker data.

    Result
    

    In the majority of patients a decrease in glycodelin abundance as well as mutational load coincided with clinical response as assessed by CT scan. Consequently, an increase of these biomarkers implicated progressive disease. Among the measured miRNAs, miR-103, miR-628-3p, and let-7e showed largely similar behavior within individual patients upon treatment initiation. The abundance of these miRNAs increased in responding patients and in a subset of patients experiencing tumor progression. Similar observations were seen for the apoptosis markers while the best results were obtained with the detection of M65.

    Conclusion
    

    Taken together, several investigated biomarkers showed high potential for an early response capturing in defined NSCLC cohorts.

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.